Garcia-Contreras Marta, Thakor Avnesh S
Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, USA.
Neural Regen Res. 2023 Jan;18(1):18-22. doi: 10.4103/1673-5374.343882.
Alzheimer's disease is a progressive and fatal neurodegenerative disorder that starts many years before the onset of cognitive symptoms. Identifying novel biomarkers for Alzheimer's disease has the potential for patient risk stratification, early diagnosis, and disease monitoring in response to therapy. A novel class of biomarkers is extracellular vesicles given their sensitivity and specificity to specific diseases. In addition, extracellular vesicles can be used as novel biological therapeutics given their ability to efficiently and functionally deliver therapeutic cargo. This is critical given the huge unmet need for novel treatment strategies for Alzheimer's disease. This review summarizes and discusses the most recent findings in this field.
阿尔茨海默病是一种进行性致命的神经退行性疾病,在认知症状出现前多年就已开始。识别阿尔茨海默病的新型生物标志物具有对患者进行风险分层、早期诊断以及监测疾病对治疗反应的潜力。一类新型生物标志物是细胞外囊泡,因为它们对特定疾病具有敏感性和特异性。此外,细胞外囊泡能够高效且功能性地递送治疗物质,因此可作为新型生物治疗剂。鉴于对阿尔茨海默病新型治疗策略存在巨大的未满足需求,这一点至关重要。本综述总结并讨论了该领域的最新发现。